168 related articles for article (PubMed ID: 18598301)
1. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers.
Jensen ML; Sjøgren P; Upton RN; Foster DJ; Bonde P; Graae C; Skram U; Stevner L; Christrup LL
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):94-101. PubMed ID: 18598301
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.
Yassen A; Olofsen E; Romberg R; Sarton E; Teppema L; Danhof M; Dahan A
Clin Pharmacol Ther; 2007 Jan; 81(1):50-8. PubMed ID: 17185999
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.
Yassen A; Olofsen E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2005 Jun; 313(3):1136-49. PubMed ID: 15701707
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.
Ing Lorenzini K; Daali Y; Dayer P; Desmeules J
Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):219-26. PubMed ID: 21995512
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2007 May; 321(2):598-607. PubMed ID: 17283225
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.
Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2006 Nov; 319(2):682-92. PubMed ID: 16855177
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers.
dos Santos FM; Gonçalves JC; Caminha R; da Silveira GE; Neves CS; Gram KR; Ferreira CT; Jacqmin P; Noël F
Ther Drug Monit; 2009 Oct; 31(5):566-74. PubMed ID: 19730280
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
Andresen T; Upton RN; Foster DJ; Christrup LL; Arendt-Nielsen L; Drewes AM
Basic Clin Pharmacol Toxicol; 2011 Apr; 108(4):274-84. PubMed ID: 21138531
[TBL] [Abstract][Full Text] [Related]
10. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers.
Zacny JP; Conley K; Galinkin J
J Pharmacol Exp Ther; 1997 Sep; 282(3):1187-97. PubMed ID: 9316825
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.
Yassen A; Olofsen E; Romberg R; Sarton E; Danhof M; Dahan A
Anesthesiology; 2006 Jun; 104(6):1232-42. PubMed ID: 16732095
[TBL] [Abstract][Full Text] [Related]
12. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.
Soyka M; Lieb M; Kagerer S; Zingg C; Koller G; Lehnert P; Limmer C; Kuefner H; Hennig-Fast K
J Clin Psychopharmacol; 2008 Dec; 28(6):699-703. PubMed ID: 19011441
[TBL] [Abstract][Full Text] [Related]
13. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients.
Dagtekin O; Gerbershagen HJ; Wagner W; Petzke F; Radbruch L; Sabatowski R
Anesth Analg; 2007 Nov; 105(5):1442-8, table of contents. PubMed ID: 17959980
[TBL] [Abstract][Full Text] [Related]
14. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
Mintzer MZ; Correia CJ; Strain EC
Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats.
Steagall PV; Pelligand L; Giordano T; Auberger C; Sear JW; Luna SP; Taylor PM
Vet Anaesth Analg; 2013 Jan; 40(1):83-95. PubMed ID: 22998333
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model.
Jensen ML; Foster D; Upton R; Grant C; Martinez A; Somogyi A
Xenobiotica; 2007 Apr; 37(4):441-57. PubMed ID: 17455115
[TBL] [Abstract][Full Text] [Related]
18. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function.
Shmygalev S; Damm M; Weckbecker K; Berghaus G; Petzke F; Sabatowski R
Drug Alcohol Depend; 2011 Sep; 117(2-3):190-7. PubMed ID: 21353749
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of buprenorphine following intravenous administration in dogs.
Krotscheck U; Boothe DM; Little AA
Am J Vet Res; 2008 Jun; 69(6):722-7. PubMed ID: 18518651
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of buprenorphine after intravenous administration in the mouse.
Yu S; Zhang X; Sun Y; Peng Y; Johnson J; Mandrell T; Shukla AJ; Laizure SC
J Am Assoc Lab Anim Sci; 2006 May; 45(3):12-6. PubMed ID: 16642964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
